Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.
Delivery of continuous, in situ–targeted, ultrahigh concentration of antibiotics (CITA) is a safe and effective therapy for patients with pocket infection who are neither suited nor willing to undergo extraction of implanted cardiovascular electronic device, reports a study.
The neutralizing antibody regdanvimab appears to be useful in the treatment of mild-to-moderate COVID-19, with a recent study showing that the drug may prevent disease worsening in patients, including those infected with the Delta variant.
In the treatment of older patients hospitalized with community-acquired pneumonia, the use of guideline-concordant antibiotic therapy significantly lowers the risk of cardiovascular death in the first year of follow-up, as reported in a study.
Oseltamivir appears to have similar efficacy as peramivir in the treatment of young children with severe influenza B, a study has found. However, oseltamivir treatment leads to better recovery and shorter hospitalization in children with severe influenza A.
Treatment with the antisense oligonucleotide bepirovirsen appears to lead to sustained loss of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA in up to 10 percent of patients with chronic HBV infection, according to the results of the phase IIb study B-Clear.